Abstract:The development of vaccines against RNA viruses has undergone a rapid evolution in recent years, particularly driven by the COVID-19 pandemic. This review examines the key roles that RNA viruses, with their high mutation rates and zoonotic potential, play in fostering vaccine innovation. We also discuss both traditional and modern vaccine platforms and the impact of new technologies, such as artificial intelligence, on optimizing immunization strategies. This review evaluates various vaccine platforms, ranging from traditional approaches (inactivated and live-attenuated vaccines) to modern technologies (subunit vaccines, viral and bacterial vectors, nucleic acid vaccines such as mRNA and DNA, and phage-like particle vaccines). To illustrate these platforms' practical applications, we present case studies of vaccines developed for RNA viruses such as SARS-CoV-2, influenza, Zika, and dengue. Additionally, we assess the role of artificial intelligence in predicting viral mutations and enhancing vaccine design. The case studies underscore the successful application of RNA-based vaccines, particularly in the fight against COVID-19, which has saved millions of lives. Current clinical trials for influenza, Zika, and dengue vaccines continue to show promise, highlighting the growing efficacy and adaptability of these platforms. Furthermore, artificial intelligence is driving improvements in vaccine candidate optimization and providing predictive models for viral evolution, enhancing our ability to respond to future outbreaks. Advances in vaccine technology, such as the success of mRNA vaccines against SARS-CoV-2, highlight the potential of nucleic acid platforms in combating RNA viruses. Ongoing trials for influenza, Zika, and dengue demonstrate platform adaptability, while artificial intelligence enhances vaccine design by predicting viral mutations. Integrating these innovations with the One Health approach, which unites human, animal, and environmental health, is essential for strengthening global preparedness against future RNA virus threats.

Revolutionizing Antiviral Therapeutics: In Silico Approaches for Emerging and Neglected RNA Viruses

New perspective of small-molecule antiviral drugs development for RNA viruses

Editorial: Antiviral options for emerging and reemerging viral diseases: current therapeutics, novel drug candidates and new approaches

The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design

Antivirals with common targets against highly pathogenic viruses

Antiviral Stratagems against HIV-1 Using RNA Interference (RNAi) Technology

Anno 2021: Which antivirals for the coming decade?

Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases

Biosimilars as antivirals: opportunities and challenges

Revolutionizing viral disease treatment: phase separation and lysosome/exosome targeting as new areas and new paradigms for antiviral drug research

Broad-spectrum antiviral inhibitors targeting pandemic potential RNA viruses

Computational repurposing of drugs for viral diseases and current and future pandemics

Exploiting the Achilles’ Heel of Viral RNA Processing to Develop Novel Antivirals

Nanotechnology-based antiviral therapeutics

Antiviral RNAi therapy: emerging approaches for hitting a moving target

Computational Approaches to Designing Antiviral Drugs against COVID-19: A Comprehensive Review

Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies

Current Progress in Antiviral Strategies.

Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems

Antiviral Approaches against Influenza Virus